Eisai started 'EWAY 2025', the medium-term business plan up to fiscal year 2025, in April 2016. For a pharmaceutical company which has conducted development of medicines over the course of many years, a decade is certainly not a long period of time. Eisai will endeavor to make steady contributions to patients with looking ahead the goal which must be reached 10 years later.
'EWAY 2025' aims to achieve the following three strategic intents:
1.Aim to support patients' thought: "I do not want to get sick. I want to know if I get sick, and I want to be cured."
2.Aim to support patients' thought: "I want to control my disease in my neighborhood and safely spend the rest of my life with peace of mind."
3.Focus on a business domain where Eisai can find out "Ricchi" based onhhcneeds and fulfill them with Eisai innovation
What is "Ricchi"
Areas where real patient needs are still unmet, and where Eisai can become a frontrunner
"Ricchi" in Oncology area
- Mesenchymal cells and tumor stromal cells
- Endothelial cells
- Myeloid cells
2.Driver gene mutation and aberrant splicing in cancer cells
Accelerate Development of Flagship Pipeline in Oncology Areas under Business Group Structure
Eisai has established business groups, end-to-end organizations that integrate functions from research and development to commercial, in the two major areas of neurology and oncology, upon the initiation of 'EWAY 2025'. One of the objectives of the establishment of business groups is to enhance productivity in business through Early Decision Making. Another is to develop Scientific Acumen, an important organizational culture, through integrated business structure which includes discovery research. Development of flagship drugs based on "Ricchi" in oncology areas is accelerating since the organizational shift to business group structure has been made.
The Oncology Business Group (OBG) will continue to make full use of its technological strength in synthetic chemistry and drug discovery targeting (for molecular targets), which fostered anticancer agents Lenvima and Halaven, to advance new drug development toward a cure for cancer.
Oncology Area–Expanding contribution to patients with Lenvima®
With Merck & Co., Inc., Kenilworth, N.J., U.S.A., co-commercialization activities have been rolled out in 18 major countries. The first indication of Lenvima® and KEYTRUDA® combination was approved and launched for endometrial carcinoma* in the United States in September 2019. We are expanding contribution to patients globally and recognized all the expected payments of 1,625 million USD by fiscal 2019. Following the recommendations in multiple cancer treatment guidance committees, we believe that the contribution to patients with an oral anticancer agent, Lenvima® may expand further.
We are conducting pivotal studies for 13 indications in 7 cancer types to expand indication of Lenvima® and KEYTRUDA® combination. Clinical studies of Lenvima® and KEYTRUDA® combination are being conducted on a large scale with estimated enrollment of a total of approximately 8,200 patients with cancer. By covering wide range of cancer types, we expect that this combination therapy may be established as a backbone therapy.
＊Advanced endometrial carcinoma that is not Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) who have disease progression following prior systemic therapy and are not candidates for curative surgery or radiation.